Recently, the combination of atezolizumab, vemurafenib, and cobimetinib have been approved by the FDA as first-line treatment for unresectable advanced BRAF V600 mutant melanoma and showed a significant increase in progression-free survival in patients [6]. The gene discussed is BRAF; the disease is melanoma.